Yun Zhang

Dr. Yun Zhang

University of Michigan Medical School, Ann Arbor, Michigan, USA
orcid
Ph.D. Candidate in Cancer Biology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
KWKatherine Weh
Katherine Weh
CHConnor Howard
Connor Howard
YZYun Zhang
Yun Zhang
BTBridget A. Tripp
Bridget A. Tripp
JCJennifer Clarke
Jennifer Clarke
Laura KrestyLaura Kresty
Laura Kresty
The gut and local esophageal microbiome progressively shift from healthy commensal bacteria to inflammation-linked pathogenic bacteria in patients with gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma (EAC). However, mechanisms by which microbial communities and metabolites contribute to reflux-driven EAC remain incompletely understood and challenging to target. Herein, we utilized a rat reflux-induced EAC model to investigate targeting the gut microbiome–esophageal metabolome axis with cranberry proanthocyanidins (C-PAC) to inhibit EAC progression. Sprague-Dawley rats, with or without reflux induction, received water or C-PAC ad libitum (700 μg/rat/day) for 25 or 40 weeks. C-PAC exerted prebiotic activity abrogating reflux-induced dysbiosis and mitigating bile acid metabolism and transport, culminating in significant inhibition of EAC through TLR/NF-κB/TP53 signaling cascades. At the species level, C-PAC mitigated reflux-induced pathogenic bacteria ( Streptococcus parasanguinis , Escherichia coli , and Proteus mirabilis ). C-PAC specifically reversed reflux-induced bacterial, inflammatory, and immune-implicated proteins and genes, including Ccl4 , Cd14 , Crp , Cxcl1 , Il6 , Il1b , Lbp , Lcn2 , Myd88 , Nfkb1 , Tlr2 , and Tlr4 , aligning with changes in human EAC progression, as confirmed through public databases. C-PAC is a safe, promising dietary constituent that may be utilized alone or potentially as an adjuvant to current therapies to prevent EAC progression through ameliorating reflux-induced dysbiosis, inflammation, and cellular damage.

17 August 2022 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
YZYun Zhang
Yun Zhang
KWKatherine M. Weh
Katherine M. Weh
CHConnor L. Howard
Connor L. Howard
JRJean-Jack Riethoven
Jean-Jack Riethoven
JCJennifer L. Clarke
Jennifer L. Clarke
Laura KrestyLaura Kresty
Laura Kresty
Isoform switching events with predicted functional consequences are common in many cancers, but characterization of switching events in esophageal adenocarcinoma (EAC) is lacking. Next-generation sequencing was used to detect levels of RNA transcripts and identify specific isoforms in treatment-naïve esophageal tissues ranging from premalignant Barrett’s esophagus (BE), BE with low- or high-grade dysplasia (BE.LGD, BE.HGD), and EAC. Samples were stratified by histopathology and TP53 mutation status, identifying significant isoform switching events with predicted functional consequences. Comparing BE.LGD with BE.HGD, a histopathology linked to cancer progression, isoform switching events were identified in 75 genes including KRAS, RNF128, and WRAP53. Stratification based on TP53 status increased the number of significant isoform switches to 135, suggesting switching events affect cellular functions based on TP53 mutation and tissue histopathology. Analysis of isoforms agnostic, exclusive, and shared with mutant TP53 revealed unique signatures including demethylation, lipid and retinoic acid metabolism, and glucuronidation, respectively. Nearly half of isoform switching events were identified without significant gene-level expression changes. Importantly, two TP53-interacting isoforms, RNF128 and WRAP53, were significantly linked to patient survival. Thus, analysis of isoform switching events may provide new insight for the identification of prognostic markers and inform new potential therapeutic targets for EAC.

24 February 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
KWKatherine Weh
Katherine Weh
YZYun Zhang
Yun Zhang
CHConnor Howard
Connor Howard
AHAmy B. Howell
Amy B. Howell
JCJennifer Clarke
Jennifer Clarke
Laura KrestyLaura Kresty
Laura Kresty
Esophageal adenocarcinoma (EAC) is a cancer characterized by rapidly rising incidence and poor survival, resulting in the need for new prevention and treatment options. We utilized two cranberry polyphenol extracts, one proanthocyanidin enriched (C-PAC) and a combination of anthocyanins, flavonoids, and glycosides (AFG) to assess inhibitory mechanisms utilizing premalignant Barrett’s esophagus (BE) and EAC derived cell lines. We employed reverse phase protein arrays (RPPA) and Western blots to examine cancer-associated pathways and specific signaling cascades modulated by C-PAC or AFG. Viability results show that C-PAC is more potent than AFG at inducing cell death in BE and EAC cell lines. Based on the RPPA results, C-PAC significantly modulated 37 and 69 proteins in JH-EsoAd1 (JHAD1) and OE19 EAC cells, respectively. AFG treatment significantly altered 49 proteins in both JHAD1 and OE19 cells. Bioinformatic analysis of RPPA results revealed many previously unidentified pathways as modulated by cranberry polyphenols including NOTCH signaling, immune response, and epithelial to mesenchymal transition. Collectively, these results provide new insight regarding mechanisms by which cranberry polyphenols exert cancer inhibitory effects targeting EAC, with implications for potential use of cranberry constituents as cancer preventive agents.

7 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YZYun Zhang
Yun Zhang
KWKatherine Weh
Katherine Weh
BTBridget Tripp
Bridget Tripp
JCJennifer Clarke
Jennifer Clarke
CHConnor Howard
Connor Howard
Laura KrestyLaura Kresty
Laura Kresty
We recently reported that cranberry proanthocyanidins (C-PACs) inhibit esophageal adenocarcinoma (EAC) by 83% through reversing reflux-induced bacterial, inflammatory and immune-implicated proteins and genes as well as reducing esophageal bile acids, which drive EAC progression. This study investigated whether C-PACs’ mitigation of bile reflux-induced transporter dysregulation mechanistically contributes to EAC prevention. RNA was isolated from water-, C-PAC- and reflux-exposed rat esophagi with and without C-PAC treatment. Differential gene expression was determined by means of RNA sequencing and RT-PCR, followed by protein assessments. The literature, coupled with the publicly available Gene Expression Omnibus dataset GSE26886, was used to assess transporter expression levels in normal and EAC patient biopsies for translational relevance. Significant changes in ATP-binding cassette (ABC) transporters implicated in therapeutic resistance in humans (i.e., Abcb1, Abcb4, Abcc1, Abcc3, Abcc4, Abcc6 and Abcc10) and the transport of drugs, xenobiotics, lipids, and bile were altered in the reflux model with C-PACs’ mitigating changes. Additionally, C-PACs restored reflux-induced changes in solute carrier (SLC), aquaporin, proton and cation transporters (i.e., Slc2a1, Slc7a11, Slc9a1, Slco2a1 and Atp6v0c). This research supports the suggestion that transporters merit investigation not only for their roles in metabolism and therapeutic resistance, but as targets for cancer prevention and targeting preventive agents in combination with chemotherapeutics.

12 May 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
YZYun Zhang
Yun Zhang
MLMichelle Lee
Michelle Lee
EJErika de Jesus
Erika de Jesus
KWKatherine Weh
Katherine Weh
CHConnor Howard
Connor Howard
Laura KrestyLaura Kresty
Laura Kresty
Cranberry proanthocyanidins (CPACs) exert potent antiinflammatory and antibacterial activities in humans and anticancer effects in preclinical models, including those targeting esophageal adenocarcinoma (EAC). This study applied proteomic profiling to investigate CPACs’ inhibitory effects on reflux‐induced EAC in a rat model. Tandem mass spectrometry was applied to protein isolated from water‐, CPAC‐, and reflux‐exposed esophagi with and without CPAC treatment. Differentially expressed proteins were identified, followed by enrichment analyses to assess CPACs’ capacity to ameliorate reflux‐induced changes in gene set hallmarks, pathways, and process networks. CPAC directly reversed 42.1% of reflux‐induced protein alterations. Gene set enrichment analysis (GSEA) revealed CPAC mitigated 11 hallmarks enriched in reflux‐induced EAC (i.e., oxidative phosphorylation, myogenesis, adipogenesis, MYC targets, and P53). Top pathways over‐represented with reflux and directly reversed by CPAC included spliceosome, metabolic pathways, and IL‐17 signaling. Transcription_mRNA processing, translation_regulation/initiation, and inflammation (i.e., kallikrein‐kinin system, neutrophil activation) dominated process networks upregulated by reflux and downregulated by CPAC. Networks exclusively altered by reflux and not mitigated by CPAC included ribosomal‐linked translation, immune response_antigen presentation, and leptin signaling. Similarly, CPAC did not reverse the reflux‐linked downregulation of ubiquinone metabolism. Identifying reflux‐induced cancer processes and pathways that CPAC fails to mitigate may inform opportunities for combination prevention efforts moving forward.